Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) Director James Foster sold 24,042 shares of Charles River Laboratories International stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the transaction, the director directly owned 31,596 shares in the company, valued at approximately $11,058,600. This represents a 43.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Stock Up 3.3%
NYSE:CRL opened at $356.76 on Tuesday. The stock has a market cap of $17.03 billion, a price-to-earnings ratio of -73.56, a PEG ratio of 3.23 and a beta of 1.40. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average price of $295.70 and a two-hundred day moving average price of $219.36. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $357.77.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. During the same period in the prior year, the business earned $3.12 EPS. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of CRL. Apollon Wealth Management LLC acquired a new stake in Charles River Laboratories International in the third quarter worth $1,481,000. Signaturefd LLC increased its stake in Charles River Laboratories International by 563.5% during the 3rd quarter. Signaturefd LLC now owns 8,865 shares of the medical research company's stock valued at $2,615,000 after purchasing an additional 7,529 shares in the last quarter. Evergreen Capital Management LLC bought a new position in shares of Charles River Laboratories International in the third quarter valued at $2,621,000. Sterling Capital Management LLC boosted its stake in Charles River Laboratories International by 350.3% during the 3rd quarter. Sterling Capital Management LLC now owns 6,642 shares of the medical research company's stock valued at $1,959,000 after purchasing an additional 5,167 shares during the last quarter. Finally, Yousif Capital Management LLC lifted its holdings in shares of Charles River Laboratories International by 721.8% in the third quarter. Yousif Capital Management LLC now owns 43,367 shares of the medical research company's stock valued at $12,794,000 after purchasing an additional 38,090 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.
Analysts Set New Price Targets
Several analysts recently issued reports on CRL shares. Evercore set a $330.00 target price on Charles River Laboratories International in a report on Friday, September 25th. UBS Group initiated coverage on Charles River Laboratories International in a report on Wednesday, September 30th. They set a "buy" rating and a $357.00 price target for the company. Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. CLSA cut shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Finally, Citigroup reaffirmed a "buy" rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $302.33.
Get Our Latest Analysis on Charles River Laboratories International
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.
Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
